Informations:
Erreur:
ID
13054
Description
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00268203
Lien
https://clinicaltrials.gov/show/NCT00268203
Mots-clés
Versions (1)
- 13/01/2016 13/01/2016 -
Détendeur de droits
CC BY-NC 3.0
Téléchargé le
13 janvier 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Lymphoma, Non-Hodgkin NCT00268203
Eligibility Lymphoma, Non-Hodgkin NCT00268203
- StudyEvent: Eligibility
Similar models
Eligibility Lymphoma, Non-Hodgkin NCT00268203
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
non-hodgkin's lymphoma
Item
histologically confirmed diagnosis of low- grade nhl or transformed low-grade nhl (tumor must be cd 20 positive).
boolean
C0024305 (UMLS CUI [1])
chemotherapy
Item
prior treatment with at least one chemotherapy regimen and have relapsed or progressed, or failed to achieve an objective response on last chemotherapy regimen.
boolean
C0392920 (UMLS CUI [1])
karnofsky performance status
Item
karnofsky performance status of at least 60% and anticipated survival of at least 3 months.
boolean
C0206065 (UMLS CUI [1])
granulocyte
Item
absolute granulocyte of >/= 1,500/mm3.
boolean
C0857490 (UMLS CUI [1])
platelet count
Item
platelet count of >/= 100,000/mm3, and not require sustained support of hematopoietic cytokines, or transfusion of blood products.
boolean
C0005821 (UMLS CUI [1])
renal function and hepatic transaminases
Item
adequate renal function (i.e., <1.5x upper limit of normal), and hepatic transaminases (ast <5 times uln).
boolean
C0232804 (UMLS CUI [1])
C0002594 (UMLS CUI [2])
C0002594 (UMLS CUI [2])
informed consent
Item
signed irb/iec-approved informed consent.
boolean
C0021430 (UMLS CUI [1])
intratrabecular marrow space
Item
patients with a mean of >25% of the intratrabecular marrow space involved with lymphoma.
boolean
C0005953 (UMLS CUI [1])
toxicity
Item
patients who received cytotoxic chemotherapy, radiation therapy, immunotherapy, or cytokine treatment within 4 weeks prior to study entry (6 weeks for nitrosurea compounds) or who exhibit persistent clinical evidence of toxicity.
boolean
C0040539 (UMLS CUI [1])
serious illness
Item
patients who have undergone stem cell or bone marrow transplant, active obstructive hydronephrosis, active infection, new york heart association class iii or iv heart disease or other serious illness that would preclude evaluation.
boolean
C0009488 (UMLS CUI [1])
hiv
Item
known hiv infection.
boolean
C0019682 (UMLS CUI [1])
pregnancy
Item
pregnant or nursing patients.
boolean
C0032961 (UMLS CUI [1])
prior malignancy
Item
patients with prior malignancy other than lymphoma, except for adequately-treated skin cancer, in-situ cervical cancer, or cancer for which the patient has been disease-free for 5 years.
boolean
C0006826 (UMLS CUI [1])
progressive disease
Item
patients with progressive disease within 1 year of irradiation arising in a field that has been previously irradiated with more than 3500 cgy.
boolean
C1335499 (UMLS CUI [1])
patients who received prior radioimmunotherapy, known brain or leptomeningeal metastases, hama positivity.
Item
patients who received prior radioimmunotherapy, known brain or leptomeningeal metastases, hama positivity.
boolean
C0085101 (UMLS CUI [1])
C0220650 (UMLS CUI [2])
C1291910 (UMLS CUI [3])
C0220650 (UMLS CUI [2])
C1291910 (UMLS CUI [3])
anti-cancer drugs or biologics
Item
patients who are receiving either approved or non-approved (through another protocol) anti-cancer drugs or biologics.
boolean
C0920425 (UMLS CUI [1])